Nuestros investigadores

María del Rocío Figueroa Mora

Publicaciones científicas más recientes (desde 2010)

Autores: Figueroa, Rocío; Alfonso, Ana; López-Picazo, José María; et al.
ISSN 1699-048X  Vol. 21  Nº 6  2019  págs. 805 - 809
PURPOSE: Thromboprophylaxis use among medical inpatients, including cancer patients, is suboptimal. We aimed to evaluate the impact of a novel multiscreen version (v2.0) of an e-alert system for VTE prevention in hospitalised cancer medical patients compared to the original software. METHODS: Prospective study including 989 consecutive adult cancer patients with high-risk of VTE. Patients were followed-up 30 days post-discharge. Two periods were defined, according to the operative software. RESULTS: E-alert v2.0 was associated with an increase in the use of LMWH prophylaxis (65.5% vs. 72.0%); risk difference (95% CI) 0.064 (0.0043-0.12). Only 16% of patients in whom LMWH prophylaxis was not prescribed lacked a contraindication. No significant differences in the rates of VTE (2.9% vs. 3.2%) and major bleeding (2.7% vs. 4.0%) were observed. CONCLUSIONS: E-alert v2.0 further increased the use of appropriate thromboprophylaxis in hospitalised cancer patients, although was not associated with a reduction in VTE incidence.
Autores: Figueroa, Rocío; Alfonso, Ana; López-Picazo, José María; et al.
Revista: PLOS ONE
ISSN 1932-6203  Vol. 13  Nº 8  2018  págs. e0200220
Hospitalized cancer patients are at high risk of venous thromboembolism (VTE). Despite current recommendations in clinical guidelines, thromboprophylaxis with low molecular weight heparin (LMWH) is underused. We performed an observational prospective study to analyse factors influencing prophylaxis use, VTE events and mortality in cancer-hospitalized patients. 1072 consecutive adult cancer patients were included in an University Hospital from April 2014 to February 2017, and followed-up for 30 days after discharge. The rate of LMWH prophylaxis was 67.6% (95% confidence interval [CI]64.7% to 70.4%), with a 2.8% rate of VTE events (95% CI 1.9% to 3.9%) and 3.5% rate of major bleeding events (95% CI 2.5% to 4.8%). 80% of VTE events occurred despite appropriate thromboprophylaxis. Overall, 30-day mortality rate was 13.2% (95% C111.2% to 15.3%). Active chemotherapy treatment, hospital stay >= 4 days, and metastatic disease were associated with a higher use of LMWH. On the contrary, patients with hematologic malignancies,anemia or thrombocytopenia were less prone to receive thromboprophylaxis. The main reasons for not prescribing LMWH prophylaxis were thrombocytopenia (23.9%) and active/recent bleeding (21.8%). The PRETEMED score, used for VTE risk stratification, correlated with 30-day mortality. There is room for improvement in thromboprophylaxis use among hospitalized-cancer patients, especially among those with hematologic malignancies. A relevant number of VTE events occurred despite prophylaxis with LMWH. Therefore, identification of risk factors for thromboprophylaxis failure is needed.
Autores: Ramirez, P. G.; Figueroa, Rocío; Malaver, F. M.; et al.
ISSN 0268-3369  Vol. 52  Nº Supl.1   2017  págs. S296
Autores: Figueroa, Rocío; Alfonso, Ana; et al.
ISSN 0390-6078  Vol. 102  Nº Supl. 2  2017  págs. 161 - 161
Autores: Marcos-Jubilar, María; Paisan-Palacio, L.; et al.
ISSN 1138-0381  Vol. 102  Nº Supl. 4  2017  págs. 351 - 352
Autores: Marcos-Jubilar, María; Erce, J. A. G. ; Martínez, Nicolás; et al.
ISSN 0390-6078  Vol. 102  Nº Supl.2  2017  págs. S879
Autores: Martínez, Nicolás; Figueroa, Rocío; et al.
ISSN 1699-3993  Vol. 52  Nº 12  2016  págs. 643-651
The CD20 marker continues to be exploited as a therapeutic target for non-Hodgkin¿s lymphoma. Obinutuzumab is part of a new generation of anti-CD20 monoclonal antibodies, which are synthesized using molecular engineering technology, resulting in novel target epitopes and unprecedented optimization of antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Rituximab is the current gold standard for anti-CD20 therapy, yet despite outstanding results published over the past decade, many patients continue to relapse after anti-CD20 regimens. Obinutuzumab is slowly positioning itself in the treatment of CD20+ B-cell neoplasms. On the basis of favorable results from the phase III GADOLIN trial, obinutuzumab was recently approved by the U.S. Food and Drug Administration in combination with bendamustine followed by obinutuzumab maintenance, for the treatment of follicular lymphoma (FL) patients who relapsed or are refractory to a rituximab-containing regimen. Additional phase III trials are underway to test obinutuzumab as a first-line anti-CD20 agent in FL with good preliminary results (GALLIUM trial); thus, it is likely that obinutuzumab will soon achieve a first-line indication. It is plausible that obinutuzumab will replace rituximab as the gold standard for chemoimmunotherapy in FL, although some safety concerns still need to be resolved. This review will address the preclinical pharmacology and the main aspects of the clinical development of obinu
Autores: García, Berta; Morales, María Isabel; Guillen Valderrama, E; et al.
ISSN 1619-7070  Vol. 43  Nº Supl.1.  2016  págs. S127 - S127
Autores: Marcos-Jubilar, María; Figueroa, Rocío; et al.
ISSN 0390-6078  Vol. 101  Nº Supl.4  2016  págs. 372 - 373
Autores: Figueroa, Rocío; Marcos-Jubilar, María; García, Berta; et al.
ISSN 0390-6078  Vol. 101  Nº Supl. 1  2016  págs. 524
Autores: Marcos-Jubilar, María; Figueroa, Rocío; et al.
ISSN 0390-6078  Vol. 101  Nº Supl.4  2016  págs. 231 - 231